ALICE: Effect of Gender Differences and Alloimmunisation on Response to Checkpoint Inhibition in Lung Cancer

ALICE: Effect of Gender Differences and Alloimmunisation on Response to Checkpoint Inhibition in Lung Cancer - ALICE

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00035724

Enrollment

300

Registered

2024-12-13

Start date

2024-08-01

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C34.9

Interventions

Group 1: Female lung cancer patients treated with checkpoint inhibitors Group 2: Male lung cancer patients treated with checkpoint inhibitors

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: written informed consent, NSCLC or SCLC, histological diagnosis, Stage IV

Exclusion criteria

Exclusion criteria: Unwilling to provide clinical history or blood sample

Design outcomes

Primary

Measure	Time frame
Response to Treatment (Routine follow up imaging, generally CT, PET-CT or MRI 6-12 weeks after first treatment and at 6-12 week intervals thereafter)	—

Secondary

Measure	Time frame
Immune Biomarkers	—

Countries

Germany

Contacts

Public ContactAmanda Tufman

LMU Klinikum, Medzinische Klinik V

amanda.tufman@med.uni-muenchen.de+4989440052590

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026